Blocking beta1-integrin to treat cancer

Jun 06, 2007

Targeting the function of a protein known as beta1-integrin might represent a novel approach to cancer treatment, according to a paper published online in The EMBO Journal this week. Blocking the action of this protein could help to prevent the formation of metastases by reducing tumour cell proliferation and inducing cell senescence.

Integrins are a family of transmembrane receptors that help maintain tissue integrity by attaching cells to the surrounding extracellular matrix and preventing them from migrating around. These proteins are also important for cell survival and proliferation, and have been shown to contribute to tumour progression in several ways.

Angelika Kren and colleagues investigated transgenic mice with insulinomas – tumours of pancreatic beta cells, which metastasize in pancreas lymph nodes. When the authors blocked beta1-integrin function in these mice, tumour cells started disseminating into lymphatic blood vessels because they were not attached to anything any more. However, the cells did not elicit metastasis and were unable to form tumours – they stopped growing and became senescent.

The authors suggest that the ablation of beta1-integrin function, and the resulting induction of cellular senescence, represent a potential therapeutic goal for the treatment of cancer. Future research should help to identify the molecular players and pathways involved.

Source: European Molecular Biology Organization

Explore further: Lung cancer test less effective in areas where infectious lung disease is more common

add to favorites email to friend print save as pdf

Related Stories

Big new iPhone brings Apple more profit

7 hours ago

Apple's largest iPhone is selling for $100 more than its other new model, but a new report says it costs Apple only $15.50 more to make the more expensive version.

Being sheepish about climate adaptation

8 hours ago

For thousands of years, man has domesticated animals, selecting the best traits possible for survival. Now, livestock such as sheep offer an intriguing animal to examine adaptation to climate change, with a genetic legacy ...

Recommended for you

XenOPAT, mouse models for personalized cancer treatment

15 hours ago

On September 8th, the company XenOPAT SL, a spin-off of the Institute of Biomedical Research (IDIBELL) and the Catalan Institute of Oncology (ICO) was established with the aim of bringing the company the latest scientific ...

User comments : 0